id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-3532-0006,FDA,FDA-2024-E-3532,Determination of Regulatory Review Period for Purposes of Patent Extension; AMTAGVI,Notice,Determinations,2026-02-13T05:00:00Z,2026,2,2026-02-13T05:00:00Z,2026-04-15T03:59:59Z,2026-02-13T19:54:42Z,2026-02974,1,0,09000064b91aa73f
FDA-2024-E-3532-0005,FDA,FDA-2024-E-3532,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-12-03T05:00:00Z,2025,12,2025-12-03T05:00:00Z,,2025-12-03T20:32:39Z,,0,0,09000064b90aa0e5
FDA-2024-E-3532-0004,FDA,FDA-2024-E-3532,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-11-05T05:00:00Z,2025,11,2025-11-05T05:00:00Z,,2025-11-05T21:54:08Z,,0,0,09000064b906919f
FDA-2024-E-3532-0003,FDA,FDA-2024-E-3532,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-08-12T04:00:00Z,2025,8,2025-08-12T04:00:00Z,,2025-08-13T00:24:57Z,,0,0,09000064b8ef8d83
FDA-2024-E-3532-0002,FDA,FDA-2024-E-3532,"Patent Extension Application from Morgan, Lewis & Bockius LLP (on behalf of lovance Biotherapeutics, Inc. (""lovance""))",Other,Application,2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T17:33:31Z,,0,0,090000648660a4b9
FDA-2024-E-3532-0001,FDA,FDA-2024-E-3532,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T17:32:16Z,,0,0,090000648660a4b8